• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    816.65 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    41 42 Next >
    Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
    The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
    Via Benzinga
    Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
    Via Benzinga
    Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
    Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects... 
    Via Benzinga
    Should You Buy the Dip on This Top Growth Stock?
    The biotech needs to overcome an issue most drugmakers face at some point. 
    Via The Motley Fool
    A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
    Via Benzinga
    Market Whales and Their Recent Bets on REGN Options
    Via Benzinga
    (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
    Via Benzinga
    $100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
    Via Benzinga
    Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
    10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
    Via Benzinga
    Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
    The S&P 500 hit record highs, fueled by Micron and Chinese stimulus. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
    The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... 
    Via Benzinga
    Exposures Product Safety
    Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
    The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
    Via Investor's Business Daily
    Exposures Product Safety
    A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
    Via Benzinga
    Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
    Via Benzinga
    Smart Money Is Betting Big In REGN Options
    Via Benzinga
    Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
    Via Benzinga
    Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
    Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap. 
    Via Benzinga
    Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
    Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... 
    Via Benzinga
    Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
    Regeneron filed an appeal after a court's decision, which was issued under seal. 
    Via Benzinga
    This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
    Via Benzinga
    Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
    The EV giant, once a big S&P 500 laggard in 2024, is now up for the year. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
    Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off. 
    Via Investor's Business Daily
    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Time To Invest And Or Trade In Bio-Tech Stocks?
    Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
    Via Talk Markets
    Topics ETFs
    Biotech Breakout: Stocks for Your Watchlist
    The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
    Via MarketBeat
    Topics ETFs
    Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
    Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    41 42 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.